{"id":"ast-201","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AST-201 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"AST-201 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:25.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06687941","phase":"PHASE1","title":"A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aptamer Sciences, Inc.","startDate":"2025-03-11","conditions":"Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung","enrollment":70},{"nctId":"NCT05794659","phase":"PHASE2","title":"Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Aston Sci. Inc.","startDate":"2023-11-15","conditions":"Advanced Ovarian Cancer","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine"],"phase":"phase_2","status":"active","brandName":"AST-201","genericName":"AST-201","companyName":"Aston Sci. Inc.","companyId":"aston-sci-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AST-201 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}